ClinicalTrials.gg
RecruitingNCT06324188Updated Jan 8, 2026

Early Atrial Fibrillation Ablation for Stroke Prevention in Patients With High Comorbidity Burden (EASThigh-AFNET 11)

An interventional study of Early atrial fibrillation ablation and Usual Care in Atrial Fibrillation, sponsored by Atrial Fibrillation Network. Recruiting at 7 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Atrial Fibrillation Network · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,312
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Atrial Fibrillation by Atrial Fibrillation Network — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Atrial Fibrillation Network.

Planned enrollment
3rd of 10
2,312 · median 718
Started
2024
the only one that year
No phase
5 of 13
2 open now
Registered
12th of 13
by date

Among the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 5 with no phase, and was the 12th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 13 studies in Atrial Fibrillation by Atrial Fibrillation Network are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Atrial Fibrillation by Atrial Fibrillation Network, or all of them as a file.
02

Study summary

EASThigh-AFNET 11 is an international, prospective, randomized, open, blinded endpoint assessment, multicenter trial (Treatment Strategy trial).

The objective of EASThigh-AFNET 11 is to investigate whether early atrial fibrillation ablation in patients with atrial fibrillation (AF) and a high comorbidity burden (CHA2DS2-VASc ≥4) reduces cardiovascular events (stroke, cardiovascular death, or heart failure events) compared to usual care.

Read the detailed description

Atrial Fibrillation (AF) is associated with high morbidity and mortality. Even on optimal anticoagulation and therapy of concomitant conditions, many patients with AF suffer cardiovascular events, especially heart failure events, stroke, and cardiovascular death. Most of these events occur in elderly patients with comorbidities. Early rhythm control, mainly delivered using antiarrhythmic drugs, reduces AF-related complications when added to anticoagulation, rate control, and treatment of comorbidities when compared to current practice that offers rhythm control mainly to reduce symptoms. The outcome-reducing effect of early rhythm control is most pronounced in patients with multiple comorbidities, quantified by a CHA2DS2-VASc score ≥ 4. Attaining sinus rhythm is the key mediator for the outcome-reducing effect of early rhythm control. Atrial fibrillation ablation controls the rhythm better than drug-based rhythm control, avoids long-term antiarrhythmic drug treatment, thus reducing polypharmacy, and may therefore be the ideal rhythm control treatment in patients with AF and a high comorbidity burden. This hypothesis needs testing. The investigator-initiated EASThigh-AFNET 11 trial evaluates the effectiveness and safety of early atrial fibrillation ablation in patients with recently diagnosed AF and a high comorbidity burden.

EASThigh-AFNET 11 is a Treatment Strategy trial randomizing 2312 patients with AF and a high comorbidity burden to early atrial fibrillation ablation or usual care to achieve a fixed number of primary endpoint events of n=527. All therapies are clinically approved. The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for worsening of heart failure. The primary safety outcome is a composite of all-cause death and serious complications of AF therapy. Secondary outcome parameters address safety, patient reported outcomes and cognitive function.

EASThigh-AFNET 11 was recommended for funding by the Expert Advisory Panel of the Global Cardiovascular Research Funders Forum (GCRFF).

03

Conditions studied

  • Atrial Fibrillation

Keywords

  • Early atrial fibrillation ablation
  • High comorbidity burden
  • CHA2DS2-VASc score
  • Early rhythm control
  • Stroke
  • Heart failure
  • Cardiovascular death
  • Cryoballoon
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

I1. AF first diagnosed within 5 years prior to enrolment and documented in body surface

I2. High comorbidity estimated by CHA2DS2-VASc score of 4 or more

I3. Patient suitable for ablation using cryoballoon ablation systems or other ablation systems with comparable efficacy and safety from Medtronic

I4. Age ≥ 18 years

I5. Provision of signed

Exclusion Criteria:

General exclusion criteria

E1. Any disease that limits to less than 1 year.

E2. Participation in another clinical trial, either within the 3 months prior to enrolment or still on-going (participation in potential sub-studies connected to this trial is permitted).

E3. Previous participation in EASThigh-AFNET 11.

E4. Pregnant women.

E5. Breastfeeding women.

E6. Drug abuse or clinically manifest alcohol abuse.

Exclusion criteria related to a cardiac condition

E7. Prior AF ablation or surgical therapy of AF.

E8. Patients not suitable for AF ablation.

E9. Patients with a history of stroke which occurred within 3 months prior to enrolment.

E10. Valve disease requiring specific therapy.

Exclusion criteria based on laboratory abnormalities

E11. Clinically manifested thyroid dysfunction requiring therapy.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,312 participants (estimated)

Study arms

  • Other
    Early atrial fibrillation ablation

    Other: Early atrial fibrillation ablation

  • Other
    Usual Care

    Other: Usual Care

Interventions

  • OtherEarly atrial fibrillation ablation

    Patients randomised to early atrial fibrillation ablation will undergo pulmonary vein isolation within 2 months after randomisation.

  • OtherUsual Care

    Usual care will consist of optimal AF therapy based on guideline recommendations and local protocols and usage.The choice of therapies and medications follows routine care in line with medical guidelines and local policies at the discretion of the treating physician and should be based on the individual medical status of each study patient.

06

What researchers measure

Primary outcomes

  1. Composite of cardiovascular complications related to AF

    It is defined as time from randomisation to the first occurrence of a composite of cardiovascular death, stroke (either ischemic or hemorrhagic), or hospitalisation for worsening of heart failure.

    Time frame: Throughout study completion, estimated at a mean of 4 years

  2. The primary safety outcome is a composite of all-cause death and serious complications of AF therapy.

    Serious Adverse Events (SAEs), including primary and secondary outcome parameters if based on clinical events, will be adjudicated by the independent Clinical Event Committee (CEC) according to standardised definitions given in the CEC charter.

    Time frame: Throughout study completion, estimated at a mean of 4 years

Secondary outcomes

  1. Number of nights spent in hospital

    Time frame: Throughout study completion, estimated at a mean of 4 years

  2. Time from randomisation to first occurrence of each of the individual components of the primary outcome

    Time frame: Throughout study completion, estimated at a mean of 4 years

  3. All-cause death

    Time frame: Throughout study completion, estimated at a mean of 4 years

  4. Serious adverse events related to AF therapy

    Time frame: Throughout study completion, estimated at a mean of 4 years

  5. Time from randomisation to first cardiovascular hospitalisation

    Time frame: Throughout study completion, estimated at a mean of 4 years

  6. Number of cardiovascular hospitalisations (over-night stay)

    Time frame: Throughout study completion, estimated at a mean of 4 years

  7. Changes in left ventricular ejection fraction

    Time frame: comparing baseline with 24 months follow up (FU)

  8. Changes in quality of life

    assessed by EQ-5D-5L

    Time frame: comparing baseline with 12 and 24 months FU

  9. Changes in quality of life

    assessed by AFEQT

    Time frame: comparing baseline with 12 and 24 months FU

  10. Changes in cognitive function

    assessed by Montreal-Cognitive-Assessment-Test

    Time frame: comparing baseline with 24 months FU

  11. Cardiac rhythm status

    sinus rhythm compared to AF

    Time frame: at 12 and 24 months FU

  12. AF pattern

    Time frame: at 12 and 24 months FU

  13. Time from randomisation to first clinical recurrence of AF

    Time frame: Throughout study completion, estimated at a mean of 4 years

  14. Time from randomisation to first progression of AF

    i. e. from paroxysmal to persistent or longstanding persistent or permanent and each of these components

    Time frame: Throughout study completion, estimated at a mean of 4 years

07

Study locations

5 of 7 sites recruiting
  • Several sites
    Multiple Locations, Australia
    Not yet recruiting
  • Several sites
    Multiple Locations, Canada
    Recruiting
  • Several sites
    Multiple Locations, Germany
    Recruiting
  • Several sites
    Multiple Locations, Netherlands
    Recruiting
  • Several sites
    Multiple Locations, Poland
    Recruiting
  • Several sites
    Multiple Locations, Spain
    Recruiting
  • Several sites
    Multiple Locations, United Kingdom
    Not yet recruiting
08

References and documents

Publications

  • Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbuchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G; EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29. PubMed 32865375 ↗
  • Rillig A, Borof K, Breithardt G, Camm AJ, Crijns HJGM, Goette A, Kuck KH, Metzner A, Vardas P, Vettorazzi E, Wegscheider K, Zapf A, Kirchhof P. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation. 2022 Sep 13;146(11):836-847. doi: 10.1161/CIRCULATIONAHA.122.060274. Epub 2022 Aug 15. PubMed 35968706 ↗
  • Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns H, Goette A, Wegscheider K, Zapf A, Camm J, Metzner A, Kirchhof P. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J. 2022 Oct 21;43(40):4127-4144. doi: 10.1093/eurheartj/ehac471. PubMed 36036648 ↗
  • Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, Roux JF, Yung D, Skanes A, Khaykin Y, Morillo C, Jolly U, Novak P, Lockwood E, Amit G, Angaran P, Sapp J, Wardell S, Lauck S, Macle L, Verma A; EARLY-AF Investigators. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021 Jan 28;384(4):305-315. doi: 10.1056/NEJMoa2029980. Epub 2020 Nov 16. PubMed 33197159 ↗
  • Andrade JG, Deyell MW, Macle L, Wells GA, Bennett M, Essebag V, Champagne J, Roux JF, Yung D, Skanes A, Khaykin Y, Morillo C, Jolly U, Novak P, Lockwood E, Amit G, Angaran P, Sapp J, Wardell S, Lauck S, Cadrin-Tourigny J, Kochhauser S, Verma A; EARLY-AF Investigators. Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. N Engl J Med. 2023 Jan 12;388(2):105-116. doi: 10.1056/NEJMoa2212540. Epub 2022 Nov 7. PubMed 36342178 ↗
  • Dickow J, Kirchhof P, Van Houten HK, Sangaralingham LR, Dinshaw LHW, Friedman PA, Packer DL, Noseworthy PA, Yao X. Generalizability of the EAST-AFNET 4 Trial: Assessing Outcomes of Early Rhythm-Control Therapy in Patients With Atrial Fibrillation. J Am Heart Assoc. 2022 Jun 7;11(11):e024214. doi: 10.1161/JAHA.121.024214. Epub 2022 May 27. PubMed 35621202 ↗
  • Dickow J, Kany S, Roth Cardoso V, Ellinor PT, Gkoutos GV, Van Houten HK, Kirchhof P, Metzner A, Noseworthy PA, Yao X, Rillig A. Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts. Circ Arrhythm Electrophysiol. 2023 May;16(5):e011585. doi: 10.1161/CIRCEP.122.011585. Epub 2023 Mar 21. PubMed 36942567 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Feb 2030, 64 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 64 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 21, 2024
StartActual
Oct 14, 2024
Primary completionEst.
Feb 2030
CompletionEst.
May 2030
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06324188
Lead sponsor
Atrial Fibrillation Network
Responsible party
Sponsor
First posted
Mar 21, 2024
Start date
Oct 14, 2024
Primary completion
Feb 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Jan 8, 2026

Study contacts

Antje Albring, Dr.
Contact
easthigh@af-net.eu
+49 251 980 1330
Anna-Katharina Quade
Contact
easthigh@af-net.eu
+49 251 980 1330
Paulus Kirchhof, Prof. Dr.
study director · University Heart and Vascular Center Hamburg, University Hospital Hamburg Eppendorf
Andreas Rillig, PD Dr.
study director · University Heart and Vascular Center Hamburg, University Hospital Hamburg Eppendorf
Jason Andrade, Prof. Dr.
principal investigator · University of British Columbia, Vancouver General Hospital, Department of Electrophysiology
André Ng, Prof. Dr.
principal investigator · Department of Cardiovascular Sciences, University of Leicester
Prash Sanders, Prof. Dr.
principal investigator · Centre for Heart Rhythm Disorders, University of Adelaide, Royal Adelaide Hospital
Volker Straub
principal investigator · Patient representative
Kevin Vernooy, Prof. Dr.
principal investigator · Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center (MUMC)
Antonia Zapf, Prof. Dr.
principal investigator · Universitätsklinikum Hamburg-Eppendorf

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion